Device Directives

The Cl process has been poorly defined in the Medical anywhere when weighed against the expected benefits.

undesirable side effects and assess whether these constitute

manufacturer under normal conditions and to determine any

Investigation (CI) is to verify the performance claimed by the

a specific medical device. The purpose of a Clinical

Clinical investigations are studies carried out in human

subjects to verify the safety and/or performance of

5. Clinical Investigation Process

Clinical investigations are studies carried out in human

subjects to verify the safety and/or performance of

a specific medical device. The purpose of a Clinical

Clinical investigations are studies carried out in human

subjects to verify the safety and/or performance of

7. Stakeholder Communication and Engagement

Stakeholder Communication and Engagement

The HPRA implementation plan for both of the new

regulations is currently in the final drafting stages.

An essential part of this implementation plan is engagement

with all stakeholders to clearly communicate the relevant

requirements of these new Regulations to ensure they are

correctly understood and implemented in a timely manner.

The HPRA is committed to working closely with stakeholders

throughout the sector on implementation and will continue

our regular dialogue with all stakeholder groups within the

regulated sector. The HPRA will, through a variety of events

and methods of communications seek to deliver relevant and

timely communications to each group within the regulated

sector. We encourage engagement from all stakeholders on

the new legislative requirements.

Stakeholders wishing to receive legislative updates including

regular communication on the new Regulations can sign up

by emailing mail@hpra.ie

All planned future stakeholder events will be published in the

“News and Events section” of our website.

Sponsorship includes all activities from the initiating

application which is transmitted via an electronic system

to all Member States in which the CI is to be conducted.

In a coordinated procedure where the sponsor submits a single

application (with defined timelines), the conduct of the study and on

requirements on the application and assessment process

are determined in line with targeted timelines set in an additional

Figure 7: Key changes in the Clinical Investigation process in the MDR

Clearer requirements on all parties

Greater detail in relation to design, conduct, reporting

Scientific approach to CIs

Clearer link with clinical evaluation / Cirodevelopment strategy

Publicly accessible information

Coordinated assessment

Clear obligations on MS in terms of assessment

What does the HPRA do?

As the regulatory authority, we monitor the safety and

compliance of all medical devices available in Ireland. Our

aim is to make sure that these products do not compromise

the health and safety of the patient or the person using

them. We are the designating authority for notified bodies

in Ireland and we also work to ensure that medical device

manufacturers are informed of and comply with the

requirements laid down in the Regulations.

The Health Products Regulatory Authority (HPRA)

Our role is to protect and enhance public and animal health

by regulating medicines, medical devices and other

health products. We provide guidance to companies and

individuals in relation to regulatory requirements particularly

if they are developing new and innovative medical devices

diagnostic or technologies that benefit patients.

Introduction

On 26th May 2017, Regulation (EU) 2017/745 on medical devices (MDR) and Regulation (EU) 2017/746 on in-vitro diagnostics (IVDR) entered into force. Both Regulations will have a staggered transitional period with some aspects, such as the notified body requirements, becoming legally binding after 6 months on 26th November 2017.

These new EU Regulations will replace the current Directives1 which have been in place for over 25 years. The MDR will become fully applicable from 28th May 2020 while the IVDR will be fully applicable from 26th May 2022.

Table 1: examples of aesthetic products that will now be considered as a medical device

Annex XVI MDR)

Aesthetic Products

Injection equipment

Coloured contact lenses

Collagen implants

Laser hair removal equipment

Skin reconstructing equipment

Tattoo removal equipment

Note: removing and planting products are excluded from this list

Practical Application of New EU Device Regulations

Changes to Scope

The scope of the Regulations has changed and now extends to all economic operators in the supply chain as well as broadening the range of products subject to the requirements of the Regulations. The MDR will now include certain medical devices without an intended medical purpose, commonly used in the beauty industry (outlined in Table 1). Medical devices incorporating non-viable human tissues and certain devices comprised of substances which are ingested to achieve their intended action will be included. The MDR also contains specific definitions relevant to genetic tests which are regulated in the EU for the first time. The MDR also includes broader definitions relevant to genetic tests and, like the MDR, places additional requirements on medical devices manufactured with hospitals, e.g. laboratory developed test.

The new Regulations specify obligations and responsibilities for all economic operators including manufacturers, importers, distributors and authorised representatives. Figure 7 illustrates some of the key obligations outlined in the legislation. It is important that economic operators ensure that they have appropriate resources, processes and systems in place to fulfil their obligations under the new Regulations.

Figure 1: Key obligations of Economic Operators


Stakeholder Communication and Engagement

The HPRA implementation plan for both of the new

regulations is currently in the final drafting stages.

An essential part of this implementation plan is engagement

with all stakeholders to clearly communicate the relevant

requirements of these new Regulations to ensure they are

correctly understood and implemented in a timely manner.

The HPRA is committed to working closely with stakeholders

throughout the sector on implementation and will continue

our regular dialogue with all stakeholder groups within the

regulated sector. The HPRA will, through a variety of events

and methods of communications seek to deliver relevant and
timely communications to each group within the regulated

sector. We encourage engagement from all stakeholders on

the new legislative requirements.

Stakeholders wishing to receive legislative updates including

regular communication on the new Regulations can sign up

by emailing mail@hpra.ie

All planned future stakeholder events will be published in the

“News and Events section” of our website.

Sponsorship includes all activities from the initiating

application which is transmitted via an electronic system

to all Member States in which the CI is to be conducted.

In a coordinated procedure where the sponsor submits a single

application (with defined timelines), the conduct of the study and on

requirements on the application and assessment process

are determined in line with targeted timelines set in an additional

Figure 7: Key changes in the Clinical Investigation process in the MDR

Clearer requirements on all parties

Greater detail in relation to design, conduct, reporting

Scientific approach to CIs

Clearer link with clinical evaluation / Cirodevelopment strategy

Publicly accessible information

Coordinated assessment

Clear obligations on MS in terms of assessment

What does the HPRA do?

As the regulatory authority, we monitor the safety and

compliance of all medical devices available in Ireland. Our

aim is to make sure that these products do not compromise

the health and safety of the patient or the person using

them. We are the designating authority for notified bodies

in Ireland and we also work to ensure that medical device

manufacturers are informed of and comply with the

requirements laid down in the Regulations.

The Health Products Regulatory Authority (HPRA)

Our role is to protect and enhance public and animal health

by regulating medicines, medical devices and other

health products. We provide guidance to companies and

individuals in relation to regulatory requirements particularly

if they are developing new and innovative medical devices

diagnostic or technologies that benefit patients.
The directive validity during transition

The transition periods outlined in the Regulations are established to afford economic operators, notified bodies and competent authorities adequate time to put in place the appropriate processes, systems and procedures by the dates of application to ensure devices placed on the market are in compliance with the new requirements. During this transition phase medical devices CE marked to the Directives can continue to be placed on the market in accordance with the criteria specified in Chapter XIV of both Regulations. Figure 2 illustrates the key timelines for certificate validity. Certificates which have been issued under the existing Directives will be valid for the period specified on the certificate so long as can be no more than 5 years.

However, in the event that a certificate is issued under the Directives just before the new Regulation comes into full application it will become void after 4 years for the MDR and 2 years for the NDavad. Devices covered by such certificates (becoming void in May 2024) can continue to be made available in the supply chain up until May 2025. These devices will be subject to the new post market surveillance requirements (e.g. reporting requirements) specified under the MDR/IVDR. Once a notified body has been designated under the new Regulations it can begin to certify devices to the new Regulations.

Incoming process changes

While the fundamental principle of the regulatory framework has not changed, there will be two Regulation bringing increased clarity, definition and enhanced assessment procedures to a dynamic medical device sector. Some of the key process changes are outlined in the following section.

1. Notified Body Designation

The requirement is the new Regulations will apply on the world already carried out under the European Commission’s Joint Assessment Scheme to help ensure that notified bodies across Europe perform to a consistent and high standard. Obligations have also been introduced for national authorities to ensure effective oversight of notified bodies based on their own on-going basis.

From the 26th November 2017, a conformity assessment body can submit an application to the authority responsible for notified bodies (the HPA) to be designated under the new Regulations as a notified body is intended. The designation process, which involves national and European procedures, is expected to take a minimum of 18 months after which notified bodies can begin to certify devices to the new requirements (Figure 3).

A similar process has been introduced for IVDs in the case of Class D IVDs. No new common specifications are available and where it is also the first certification for that type of device. In such cases, the notified body consults the expert panel on the performance evaluation report of the manufacturer and the timeframe for the expert panel to deliver an opinion is the same as that specified in the MDR (60 days). In the conformity assessment procedure for Class D IVDs, at the same time, a designated EU reference laboratory verifies the performance claimed by the manufacturer who shall provide an opinion within 60 days.

1. Notified Body Designation

Manufacturers should examine their product portfolio to assess how they may need to change in order to comply with the new requirements. It is recommended that manufacturers talk with their notified body to ensure they understand the process for assessment and certification by a notified body prior to being placed on the market.

2. Scrutiny

Until the date of full application of the new Regulations, 26th May 2020 for medical devices and 26th May 2022 for IVDs, devices can continue to be certified and placed on the market according to the current Directives. Alternatively manufacturers can, on a voluntary basis, certify their devices to the new Regulations in advance of the date of full application.

It is recommended that manufacturers talk with their notified body to ensure they understand the process for re-certification and are fully prepared for the MDR and NDavad. Both IVD manufacturers and IVD designated notified bodies will be particularly important under the MDR. Under the new Regulation the majority of IVDs will now be subject to assessment and certification by a notified body prior to being placed on the market. IVD manufacturers should review their product portfolio to determine which devices may be subject to this scrutiny process.

3. IVD Classification

The IVDR introduces a rule-based classification system for IVDs. IVDs will now be classified into four different classes (Class A to Class D) and notified bodies will be required to undertake assessment and certification by a notified body. Type B IVDs and IVDs are also subject to the notification and assessment procedures required to be subject to the notified body. The IVDR introduces a rule-based classification system for IVDs.

IVDs will now be classified into four different classes (Class A to Class D) and notified bodies will be required to undertake assessment and certification by a notified body. Type B IVDs and IVDs are also subject to the notification and assessment procedures required to be subject to the notified body.

4. Vigilance Reporting

The new Regulations set out specific requirements for manufacturers to establish and maintain a post-market surveillance and vigilance system. As part of their system there is a requirement to report serious incidents and Field Safety Corrective Actions to the relevant Competent Authority (the HPA in Ireland through the centralised database). As a general rule, the time period for reporting shall take account of the severity of the serious incident (see Figure 4). It is important to note that the timeframe for reporting serious incidents has been reduced compared to that specified in the European Commission guidelines on a medical devices vigilance system. If after becoming aware of a potentially reportable incident, the manufacturer is uncertain about whether the incident is reportable, the manufacturer should submit a report within the timeframe required as set out in Figure 4. Medical device users are also encouraged to report incidents. Suspected incidents or complaints may also be reported to the importer or the distributor of the device. This information shall be shared with the manufacturer of the device.
Certificates which have been issued under the existing criteria specified in Chapter X of both Regulations continue to be placed on the market in accordance with the repealed Directives 93/42/EEC, Directive 98/79/EEC and Directive 90/385/EEC of application to ensure devices placed on the market are in conformity and competent authorities adequate time to put in place the procedures to conduct the new requirements. The transition periods outlined in the Regulations are as follows:

- For medical devices: 2 years for the MDR and 2 years for the IVDR.
- For IVDs: 2 years for the IVDR.

The transition periods outlined in the Regulations are intended to provide manufacturers and notified bodies ample time to prepare for the new requirements. Once notified bodies have been designated under the new Regulations, they can issue CE certificates for medical devices and IVDs.

Until the date of full application of the new Regulations, 26th May 2020 for medical devices and 26th May 2022 for IVDs, devices can continue to be certified and placed on the market in accordance with the conditions of the existing CE certificates issued under the repealed Directives. Medical device manufacturers can, on a voluntary basis, certify their devices to the new Regulations in advance of the date of full application.

### 1. Notified Body Designation

The requirements in the new Regulations on the work already carried out under the European Commission’s Joint Assessment Scheme to help ensure that notified bodies across Europe perform to a consistent and high standard. Ongoing and planned conformity assessments for notified bodies and their activities are monitored by national and European authorities to ensure effective oversight of notified bodies based on their conformity assessment results. There is a requirement to submit to the notified body an unannounced on-site inspection (Figure 4).

Once a notified body has been designated under the new Regulations it can begin to certify devices to the new Regulations. Notified bodies will now require a Notified Body assessment. It is important to note that the timeframe for the expert panel to deliver an opinion is the same as that specified in the MDR (60 days). In the conformity assessment procedure for Class III IVDs, at the same time, a designated EU reference laboratory verifies the performance claimed by the manufacturer who shall provide an opinion within 60 days.

A similar process has been introduced for IVDs in the case of Class D IVDs where no common specifications are available and where it is also the first certification for that type of device. In such cases, the notified body consults the expert panel on the performance evaluation report of the manufacturer and the reference laboratory to ensure that a notified body is indeed able to assess the performance and safety of these devices.

### 2. Scrutiny

High risk IVDs, Class III implantable devices and devices intended to administer or remove a medicine that do not have common specifications identified, will now be subject to an extra type of scrutiny, a pre-market assessment, by an expert panel during the notified body assessment process. A similar process has been introduced for IVDs in the case of Class D IVDs where no common specifications are available and where it is also the first certification for that type of device. In such cases, the notified body consults the expert panel on the performance evaluation report of the manufacturer and the reference laboratory to ensure that a notified body is indeed able to assess the performance and safety of these devices. This process will provide support to the notified body to ensure that it is able to assess the performance and safety of these devices. This process will provide support to the notified body to ensure that it is able to assess the performance and safety of these devices. The IVDR introduces a rule-based classification system for IVDs. IVDs will now be classified into four different classes (Figure 5). Classes A and B will not be subject to conformity assessment prior to being placed on the market. Class A IVDs are subject to a conformity assessment based on the conformity assessment procedure for IVDs (Class A IVDs) prior to being placed on the market. Class A IVDs will now be subject to an unannounced on-site inspection (Figure 4). Medical device users are also encouraged to report incidents. Suspected incidents or complaints may also be reported to the importer or the distributor of the device. This information shall be shared with the manufacturer of the device.

### 3. IVD Classification

The IVDR introduces a rule-based classification system for IVDs. IVDs will now be classified into four different classes (Figure 5). Classes A and B will not be subject to conformity assessment prior to being placed on the market. Class A IVDs are subject to a conformity assessment based on the conformity assessment procedure for IVDs (Class A IVDs) prior to being placed on the market. Class A IVDs will now be subject to an unannounced on-site inspection (Figure 4). Medical device users are also encouraged to report incidents. Suspected incidents or complaints may also be reported to the importer or the distributor of the device. This information shall be shared with the manufacturer of the device.

### 4. Vigilance Reporting

The new Regulations set out specific requirements for manufacturers to establish and maintain a post-market surveillance and vigilance system. As part of their system, there is a requirement to report serious incidents and Field Safety Corrective Action reports to the relevant Competent Authority. There is a requirement to notify the manufacturer of the device to the Competent Authority. The HPRA in Ireland through the centralised database. As a general rule, the time period for reporting is uncertain about whether the incident is reportable. The manufacturer should submit a report within the timeframe required as set out in Figure 6. Medical device users are also encouraged to report incidents. Suspected incidents or complaints may also be reported to the importer or the distributor of the device. This information shall be shared with the manufacturer of the device.
The certificate validity during transition

The transition periods outlined in the Regulations are established to afford economic operators, notified bodies and competent authorities adequate time to put in place the appropriate processes, resources and systems by the date of application to ensure devices placed on the market are in compliance with the new requirements. During this transition phase medical devices CE marked to the Directives can continue to be placed on the market in accordance with the criteria specified in Chapter 4 of both Regulations. Figure 2 illustrates the key timeframes for certificate validity. Certificates which have been issued under the existing Directives will be valid for the period specified on the certificate which can be up to a maximum of 5 years. However, in the event that a certificate is issued under the Directives just before the new Regulation comes into full application it will become valid after 4 years for the MDR and 2 years for the NDD. Devices covered by such certificates (becoming valid in May 2020) can continue to be made available in the supply chain up until May 2023. These devices will be subject to the new post market surveillance requirements (e.g. reporting requirements) specified under the new MDR/AIVD. Once a notified body has been designated under the new Regulations it can begin to certify devices to the new Regulations.

Incoming Process Changes

While the fundamental principle of the regulatory framework has not changed, the two Regulations bring increased clarity, definition and enhanced assessment procedures to a dynamic medical device sector. Some of the key process changes are outlined in the following section.

1. Notified Body Designation

The requirements in the new Regulations applied on the work already carried out under the European Commission’s Joint Assessment Scheme to help ensure that notified bodies across Europe perform to a consistent and high standard. Obligations have also been introduced for national authorities to ensure effective oversight of notified bodies based on their risk on going basis.

From the 26th November 2017, a conformity assessment body can submit an application to the authority responsible for notified bodies (the HPA) to be designated under the new Regulations as a notified body is intended. The designation process, which involves national and European assessments, is expected to take a minimum of 18 months after which notified bodies can begin to certify devices to the new requirements (Figure 3).

2. Scrutiny

High risk devices, Class III implantable devices and devices intended to administer or remove a medicine that do not have common specifications identified, will now be subject to an extra layer of scrutiny, or pre-market assessment. By an expert panel during the notified body assessment process (Figure 2). The scrutiny process will provide an additional pre-market assurance to the manufacturer that the notified body has the expertise and competence to deliver an opinion within the timeframe for the expert panel to deliver an opinion is the same as that specified in the MDR (60 days). In the conformity assessment procedure for Class III IVDs, at the same time, a designated EU reference laboratory will verify the performance claims by the manufacturer who shall provide an opinion within 60 days.

A similar process has been introduced for IVDs in the case of Class D IVDs where no common specifications are available and where it is also the first certification for that type of device. Such notifications will be subject to an expert panel on the performance evaluation report of the manufacturer and the reference laboratory for the expert panel to deliver an opinion is the same as that specified in the MDR (60 days). In the conformity assessment procedure for Class D IVDs where no common specifications are available, the time period for reporting the performance claims by the manufacturer will be extended to 120 days.

3. IVD Classification

The new Regulations build on the work already carried out under the European Commission’s Joint Assessment Scheme to help ensure that notified bodies across Europe perform to a consistent and high standard. The new Regulations set out specific requirements for manufacturers to establish and maintain a post market surveillance and vigilance system. As part of their system there is a requirement to report serious incidents and Field Safety Corrective Actions to the relevant Competent Authority (the HPA in Ireland) through the centralised database. As a general rule, the time period for reporting shall account of the severity of the serious incident (see Figure 4). It is important to note that the timeframe for reporting serious incidents has been reduced compared to that specified in the European Commission guidelines on a medical device vigilance system. If, after becoming aware of a potentially reportable incident, the manufacturer is uncertain about whether the incident is reportable, the manufacturer should submit a report within the timeframe required as set out in Figure 6. Medical device users are also encouraged to report incidents. Suspected incidents or complaints may also be reported to the importer or the distributor of the device. This information shall be shared with the manufacturer of the device.

4. Vigilance Reporting

The new Regulations set out specific requirements for manufacturers to establish and maintain a post market surveillance and vigilance system. As part of their system there is a requirement to report serious incidents and Field Safety Corrective Actions to the relevant Competent Authority (the HPA in Ireland) through the centralised database. As a general rule, the time period for reporting shall account of the severity of the serious incident (see Figure 4). It is important to note that the timeframe for reporting serious incidents has been reduced compared to that specified in the European Commission guidelines on a medical device vigilance system. If, after becoming aware of a potentially reportable incident, the manufacturer is uncertain about whether the incident is reportable, the manufacturer should submit a report within the timeframe required as set out in Figure 6. Medical device users are also encouraged to report incidents. Suspected incidents or complaints may also be reported to the importer or the distributor of the device. This information shall be shared with the manufacturer of the device.
5. Clinical Investigation Process

Clinical investigations are studies carried out in human subjects to verify the safety and/or performance of a specific medical device. The purpose of a Clinical Investigation (CI) is to verify the performance claimed by the manufacturer under normal conditions and to determine any risks when weighed against the expected benefits. The CI process has been poorly defined in the Medical Device Directives and included many specific provisions to ensure that people enrolled in clinical studies are appropriately protected. In addition, a clinical investigation report summarising the study results will be available to all stakeholders involved in CIs such as subjects, sponsors, manufacturers, and competent authorities and for the principal investigator.

Further information

For multi-site investigations, the MDR introduces a voluntary requirement on the application and assessment process. The coordinated procedure means that there is one lead competent authority and for the principal investigator. The coordinated procedure involves that an electronic system is developed to transmit an application which is transmitted via an electronic system to all Member States in which the D is to be conducted. The coordinated procedure means that there is one level or co-ordinating member state responsible for coordinating the assessment of the CI application.

What does the HPRA do?

As the regulatory authority, we monitor the safety and compliance of all medical devices available in Ireland. Our aim is to make sure that these products do not compromise the health and safety of the public. We are the designating authority for notified bodies in Ireland and all work to ensure that all medical device manufacturers are informed of and comply with the requirements laid down in the Regulations.

The Health Products Regulatory Authority (HPRA)

Our role is to protect and enhance public and animal health by regulating medicines, medical devices and other health products. We provide guidance to companies and individuals in relation to regulatory requirements particularly if they are developing new and innovative medical devices or diagnostics that can benefit patients.

In the assessment of the CI application, the HPRA will assess the study design and methods of communication seek to deliver relevant and timely communications to each group within the regulated sector. We encourage engagement from all stakeholders on the new legislative requirements.

Changes to Scope

The scope of the Regulations has changed and now extends to all economic operators in the supply chain and as broadening the range of products subject to the requirements of the Regulations. The MDR will now include certain aesthetic products without an intended medical purpose, commonly used in the beauty industry (outlined in Table 1). Medical devices incorporating non-viable human tissues and certain devices comprised of substances which are ingested to achieve their intended effect will be covered. The MDR will also contain specific requirements for the reprocessing of single-use devices. The IVDR includes mandatory provisions for the reprocessing of single-use devices. The IVDR will now include certain aesthetic products without an intended medical purpose, commonly used in the beauty industry (Annex XVI MDR).

Practical Application of New EU Device Regulations

Introduction

On 26th May 2017, Regulation (EU) 2017/745 on medical devices (MDR) and Regulation (EU) 2017/746 on in-vitro diagnostics (IVDR) entered into force. Both Regulations will have a staggered transitional period with some aspects, such as the notified body requirements, becoming legally binding after 6 months on 26th November 2017. These new EU Regulations will replace the current Directives which have been in place for over 25 years. The MDR will become fully applicable from 26th May 2020 while the IVDR will be fully applicable from 26th May 2022.

Figure 1: Key obligations of Economic Operators

Table 1: examples of aesthetic products that will now be considered as a medical device

An essential part of this implementation plan is engagement with all stakeholders to clearly communicate the relevant and methods of communication seek to deliver relevant and timely communications to each group within the regulated sector. We encourage engagement from all stakeholders on the new legislative requirements.

Stakeholder Communication and Engagement

The HPRA's implementation plan for both of the new regulations is currently in the final drafting stage. An essential part of this implementation plan is engagement with all stakeholders to clearly communicate the relevant and timely communications to each group within the regulated sector. We encourage engagement from all stakeholders on the new legislative requirements.

Stakeholders wishing to receive legislative updates including regular communications on the new Regulations can sign up by emailing eudr@hpra.ie. A planned future stakeholder event will be published in the "News and Events section" of our website.

Conclusion

The new EU Device Regulations will replace the current Directives which have been in place for over 25 years. The MDR will become fully applicable from 26th May 2020 while the IVDR will be fully applicable from 26th May 2022.

Stakeholder Communication and Engagement

The HPRA's implementation plan for both of the new regulations is currently in the final drafting stage. An essential part of this implementation plan is engagement with all stakeholders to clearly communicate the relevant and timely communications to each group within the regulated sector. We encourage engagement from all stakeholders on the new legislative requirements.

Stakeholders wishing to receive legislative updates including regular communications on the new Regulations can sign up by emailing eudr@hpra.ie. A planned future stakeholder event will be published in the "News and Events section" of our website.

In the assessment of the CI application, the HPRA will assess the study design and methods of communication seek to deliver relevant and timely communications to each group within the regulated sector. We encourage engagement from all stakeholders on the new legislative requirements.

Stakeholders wishing to receive legislative updates including regular communications on the new Regulations can sign up by emailing eudr@hpra.ie. A planned future stakeholder event will be published in the "News and Events section" of our website.

What does the HPRA do?

As the regulatory authority, we monitor the safety and compliance of all medical devices available in Ireland. Our aim is to make sure that these products do not compromise the health and safety of the public. We are the designating authority for notified bodies in Ireland and all work to ensure that all medical device manufacturers are informed of and comply with the requirements laid down in the Regulations.

The Health Products Regulatory Authority (HPRA)

Our role is to protect and enhance public and animal health by regulating medicines, medical devices and other health products. We provide guidance to companies and individuals in relation to regulatory requirements particularly if they are developing new and innovative medical devices or diagnostics that can benefit patients.

In the assessment of the CI application, the HPRA will assess the study design and methods of communication seek to deliver relevant and timely communications to each group within the regulated sector. We encourage engagement from all stakeholders on the new legislative requirements.

Stakeholder Communication and Engagement

The HPRA's implementation plan for both of the new regulations is currently in the final drafting stage. An essential part of this implementation plan is engagement with all stakeholders to clearly communicate the relevant and timely communications to each group within the regulated sector. We encourage engagement from all stakeholders on the new legislative requirements.

Stakeholders wishing to receive legislative updates including regular communications on the new Regulations can sign up by emailing eudr@hpra.ie. A planned future stakeholder event will be published in the "News and Events section" of our website.

In the assessment of the CI application, the HPRA will assess the study design and methods of communication seek to deliver relevant and timely communications to each group within the regulated sector. We encourage engagement from all stakeholders on the new legislative requirements.

Stakeholders wishing to receive legislative updates including regular communications on the new Regulations can sign up by emailing eudr@hpra.ie. A planned future stakeholder event will be published in the "News and Events section" of our website.

What does the HPRA do?

As the regulatory authority, we monitor the safety and compliance of all medical devices available in Ireland. Our aim is to make sure that these products do not compromise the health and safety of the public. We are the designating authority for notified bodies in Ireland and all work to ensure that all medical device manufacturers are informed of and comply with the requirements laid down in the Regulations.

The Health Products Regulatory Authority (HPRA)

Our role is to protect and enhance public and animal health by regulating medicines, medical devices and other health products. We provide guidance to companies and individuals in relation to regulatory requirements particularly if they are developing new and innovative medical devices or diagnostics that can benefit patients.
Stakeholder Communication and Engagement

The HPRA implementation plan for both of the new regulations is currently in the final drafting stages. An essential part of this implementation plan is engagement with all stakeholders to clearly communicate the relevant requirements of these new Regulations to ensure they are correctly understood and implemented in a timely manner.

The HPRA is committed to working closely with stakeholders throughout the sector on implementation and will continue our regular dialogue with all stakeholder groups within the regulated sector. The HPRA will, through a variety of events and methods of communication seek to deliver relevant and timely communications to each group within the regulated sector. We encourage engagement from all stakeholders on the new legislative requirements. Stakeholders wishing to receive legislative updates including regular communications on the new Regulations can sign up to our regular communications by emailing eudr@hpra.ie.

The Health Products Regulatory Authority (HPRA)

Our role is to protect and enhance public and animal health by regulating medicines, medical devices and other health products. We provide guidance to companies and individuals in relation to regulatory requirements particularly if they are developing new and innovative medical devices or diagnostics that will benefit patients.

What does the HPRA do?

As the regulatory authority, we monitor the safety and compliance of all medical devices available in Ireland. Our role is to protect and enhance public and animal health by regulating medicines, medical devices and other health products. We provide guidance to companies and individuals in relation to regulatory requirements particularly if they are developing new and innovative medical devices or diagnostics that will benefit patients.

Stakeholders wishing to receive legislative updates including regular communications on the new Regulations can sign up to our regular communications by emailing eudr@hpra.ie.

Further information

See the ‘New EU Device Legislation’ tab in the Medical Devices section of www.hpra.ie for detailed information.

Changes to Scope

The scope of the Regulations has changed and now extends to all economic operators in the supply chain and as broadening the range of products subject to the requirements of the Regulations. The MDR will now include certain non-viable human tissues and certain devices comprised of substances which are ingested to achieve their intended action will be included. The MDR also contains specific provisions outlining some of the key changes for CIs in the MDR and includes clear requirements laid down in the Regulations. The public to improve transparency. Figure 1 illustrates some of the key changes for CIs in the MDR and includes clear requirements laid down in the Regulations. The public to improve transparency. Figure 1 illustrates some of the key changes for CIs in the MDR and includes clear requirements laid down in the Regulations.
Economic Operators Obligations under the new EU Device Regulations (EUDR) Legislation

The new EUDR elaborates and strengthens the responsibilities and obligations of all economic operators. For the first time distributors are included within the scope of the new EUDR and distributor obligations are specifically called out within the Regulations and confers additional obligations and responsibilities on all economic operators. The Regulations build on the New Legislative Framework for the Marketing of Products and provide economic operators with greater legal clarity, in particular, where they assume the manufacturers’ obligations or when an operator is considered the manufacturer when certain activities are carried out. This will help improve regulatory compliance by economic operators and help ensure the safety and performance of the device throughout the supply chain. The EUDR obligations range from ensuring proper storage and transportation of devices while under their care to greater verification, traceability and reporting requirements.

Who are Economic operators?

Economic operators under the EUDR refers to manufacturers, importers and distributors. It includes the manufacturers’ authorised representative established within the EU who has received and accepted a written mandate to act on behalf of a manufacturer based outside of the EU. The manufacturer is ultimately responsible for ensuring that a device is compliant with the relevant legislation. A summary of other economic operators’ responsibilities can be found below.

Summary of the responsibilities of Authorised Representatives, Distributors and Importers:

<table>
<thead>
<tr>
<th>Economic operator</th>
<th>Authorised Representative</th>
<th>Distributor</th>
<th>Importer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Verify:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Devices is CE marked</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>EU Declaration of Conformity &amp; technical documentation are drawn up</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Correct conformity assessment procedure has been carried out</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Labelling &amp; accompanying information (IFU)</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>MFR has assigned the UDI</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>Importer has included name &amp; contact details (Art. 13.3 EUDR)</td>
<td>X</td>
<td></td>
<td>X</td>
</tr>
<tr>
<td>MFR is identified &amp; authorised representative has been assigned</td>
<td></td>
<td></td>
<td>X</td>
</tr>
</tbody>
</table>

Additional requirements:

- Have a person responsible for regulatory compliance in place: X
- Storage and transportation requirements fulfilled: X
- Maintain a register of complaints: X
- Inform MFR when device presents a serious risk or is not in conformity: X
- Eudamed Registration obligations: X
- Reporting requirements (serious incidents/serious risk): X

Note: Reporting is encouraged by all Economic Operators

- Cooperation with Competent Authorities (preventative/corrective action): X
- Store UDI for Class III implantable devices: X
- Identification within the supply chain (Art. 25 EUDR): X

---

1 Regulation (EU) 2017/745 on medical devices (MDR) and Regulation (EU) 2017/746 on in vitro diagnostics (IVDR).

This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.
Classification under the Medical Devices Regulation (MDR)
Regulation (EU) 2017/745

Medical devices are stratified according to risk into four classes with Class I being the lowest risk and Class III the highest:

<table>
<thead>
<tr>
<th>DEVICE CLASS</th>
<th>EXAMPLES OF APPLICATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class III</td>
<td>Complex joint implants, drug eluting stents, coronary valves, breast implants, surgical meshes, active implantables</td>
</tr>
<tr>
<td>Class IIb</td>
<td>Peripheral Bare Metal Stents (BMS), bone fixation plates, dressings for chronic ulcerated wounds</td>
</tr>
<tr>
<td>Class IIa</td>
<td>Contact lenses (short-term), ECG machines, electronic BP monitoring, dental fillings</td>
</tr>
<tr>
<td>Class I</td>
<td>Wheelchairs, simple wound dressings, stethoscopes, ECG electrodes, syringes. Sub-divided into sterile devices (Is) and those with a measuring function (Im)</td>
</tr>
</tbody>
</table>

The MDR sets out 22 classification rules¹ which are used to classify devices based on risk criteria:

- Degree/type of invasiveness
- Duration of contact
- Site of contact/anatomical locations
- Specific characteristics- active/non-active, single use/reusable; combined with medicinal substance; incorporating animal tissues.

The application of these rules will depend on the intended purpose of the device and will replace the 18 rules² currently used under the General Medical Devices Regulation. This rule based classification system covers 30,000 difference types of medical device and influences: pre-market requirements, the conformity assessment route, clinical data requirements as well as post-market obligations.

In addition, certain existing devices have been up-classified due to the nature of risk associated with the specific devices. Examples of up-classifications can be found in Rule 8.

Devices used together (e.g. same procedure) are classified in their own right. Device accessories are classified in their own right and separately to the device with which they are used.

Software which drives or influences a device falls automatically into the same class as the device.

¹ Regulation (EU) 2017/745, Article 51 & Annex VIII
² Directive 93/42/EEC, Article 9 & Annex IX

This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.
The classification system for IVDs in accordance with the IVD Directive differs from the medical devices classification system as it is list based rather than a risk based rules approach. This list based system is provided in Annex II of the IVD Directive.\(^3\)

With the introduction of the IVDR the classification system has been modelled on the Global Harmonisation Task Force (GHTF) Guidelines with some modifications. IVDR classification adopts a similar system to the MDR risk based rules approach with four distinct classes now introduced. Class A is the lowest risk and Class D is the highest.

Annex VIII of the IVDR sets out the 7 classification rules based on intended purpose & inherent risk:

<table>
<thead>
<tr>
<th>IVD CLASS</th>
<th>EXAMPLES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Class D</td>
<td>HIV, ABO blood grouping, Rhesus testing</td>
</tr>
<tr>
<td>Class C</td>
<td>Companion diagnostics, tests for screening, diagnosis &amp; staging of cancer</td>
</tr>
<tr>
<td>Class B</td>
<td>Pregnancy or fertility self-test</td>
</tr>
<tr>
<td>Class A</td>
<td>Products for general laboratory use &amp; Specimen receptacles</td>
</tr>
</tbody>
</table>

The new classification system and the broadening of the scope of the IVDR means that approximately 90% of IVDs will be subject to review by a notified body to some degree for the conformity assessment process under the IVDR. This includes, for example, genetic tests that provide information on predisposition to a medical condition or disease and tests that provide information to predict treatment response or reactions (companion diagnostics). The conformity assessment for each device class is set out in Chapter V of the IVDR.

---

\(^3\) Directive 98/79/EC on in vitro diagnostic medical devices

This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.
What is medical device innovation?

The European medical technology sector is globally recognised as highly innovative. Medical device innovation plays an important role in the enhancement of public health by allowing new diagnostic and treatment options to be developed while simultaneously increasing the practical benefits for patients and health providers. While much medical technology innovation is iterative, new technologies frequently emerge offering new possibilities and addressing unmet or underserved clinical needs.

The European regulatory system for medical devices has always facilitated a suitable environment to promote high levels of innovation. Indeed based on the number of patents filed on an annual basis at the European Patents Office, the medical technology sector exceeds innovation levels in comparison to other health products and related sectors. The new European Regulations on medical devices (detailed below) will preserve and nurture this innovation-friendly environment through initiatives like: coordinated EU assessment of clinical investigation applications (research), clearer and better defined requirements for clinical data and EU level advisory services for new product and clinical development strategies. These new Regulations will further protect and enhance public health by ensuring the safety and performance of medical devices throughout their lifecycle while supporting innovation and facilitating market access in an appropriate and timely manner.

The primary function of the HPRA is the protection, and enhancement of public health. The interplay of this responsibility with the need to ensure that innovative medical device technology is made available to European patients is a key focus for us as regulators.

Why is medical device innovation important?

Innovation plays an important role in medical device development for a number of reasons:

- Medical devices tend to develop through iterative change – i.e. they evolve and are often modified.
- The lifecycle for a typical medical device is less than 2 years.
- The technology is rapidly changing.
- The medical device industry drives innovation.

The interplay between the new Regulations and innovation

The Medical Devices Regulation 2017/745 (MDR) and In Vitro Diagnostic Devices Regulation 2017/746 (IVDR) were formally published in the Official Journal of the European Union on 5th May 2017. These Regulations incorporate a number of important improvements to the regulatory system in Europe. The importance of innovation is recognised in both the MDR and IVDR which note that a revised regulatory framework can ensure a high level of safety and health whilst supporting innovation.

How does the HPRA support Medical Device innovation?

Supporting innovation is a strategic priority for the HPRA. This reflects both the high density of innovative companies across the life sciences sector in Ireland and the presence of an extensive research, development and innovation sector within academia and other areas. Strong links between academia, industry and regulators will help to encourage and support innovation.

The HPRA offers support to medical device innovation in the form of:

- Preliminary meetings with device innovators. In these meetings, the HPRA offers general regulatory support to SMEs / academic research groups or spin-outs etc. as these groups are often scientifically focussed and may have a limited knowledge of regulations.
- Pre-submission meetings. In these meetings, the HPRA offers general advice to sponsors of clinical investigations planning a submission to HPRA in the near future.
- The HPRA accepts requests from manufacturers for the classification of a medical device, drug-device combination or borderline product prior to the intended submission of an application for CE marking to a notified body or prior to notification regarding the register of Class I devices. All classification requests are subject to a fee.
• The HPRA Innovation office. This is a facility whereby a question can be submitted to the HPRA Innovation Office relating to any of the healthcare products which the HPRA regulates.

• The Innovation Office will also publish general updates and information about regulatory and scientific issues related to innovation.

How do I submit an innovation query to the HPRA?

• Anyone developing an innovative product can submit a query to the HPRA.

• Our Innovation Office will act as an initial point of contact for such queries and requests for advice in relation to innovative health products or technologies.

• Queries related to innovative medical technology or other health products should be submitted using our online enquiry form. This is available via the Innovation Office webpage which can be accessed through our website www.hpra.ie

• Alternatively you can e-mail us at innovationoffice@hpra.ie

• We aim to respond to all queries as soon as possible and within 20 working days. If a longer review period is necessary, we will contact you to inform you of the expected timeline for responding.

• All queries will be treated as confidential.

The Health Products Regulatory Authority (HPRA) - What we do?

Our role is to protect and enhance public and animal health by regulating medicines, medical devices and other health products.

We use our scientific and clinical expertise to review and monitor health products available in Ireland or exported abroad. Our aim is to make sure that the health products we regulate are as safe as possible and do what they are intended to do.

Further information

If you have any questions about the innovation supports available from the HPRA, please e-mail: innovationoffice@hpra.ie

Specific queries relating to medical device legislative requirements, clinical investigations (research) or other HPRA device services please contact devices@hpra.ie.

Specific queries on the new medical device Regulations on medical devices can be submitted to eudr@hpra.ie

This guide does not purport to be an interpretation of law and/or regulations and is for guidance purposes only.